Immatics presenting at CHI’s 7th Annual Immuno-Oncology Summit Europe
Jun 20 - Jun 22, 2023
Join us at the Annual Immuno-Oncology Summit in London! The Summit comprises 4 conference programs, from strategies on Modulating the Tumour Microenvironment; to various treatment modalities including Next-Generation Cell-Based Immunotherapies; Bispecific and Multi-Specific Antibody Therapeutics, and Gamma Delta Immunotherapy.
Tuesday, June 20, 4:30 PM
- Session: Modification and Engineering of Gamma Delta Constructs
- Speaker: Steffen Walter, PhD, COO, Immatics
- Presentation: Allogeneic gamma delta (Gd) T cells bear promises for developing off-the-shelf T cell therapies for cancer through leveraging their unique functional attributes. Gd T cell therapy development requires precise balancing between anti-tumor armoring and cloaking against the patient's immune cells. Immatics is building on its expertise in TCR-based tumor targeting and adoptive T cell therapies to develop such product candidates via our proprietary ACTallo platform through data-driven gene engineering and highly optimized manufacturing.
We are looking forward to meeting you!
For more information visit the event's homepage.